Menu
Search icon
  1. Home Page
    2. ›
  2. Counties
    3. ›
  3. New York
    4. ›
  4. 10004
    5. ›
  5. INTERNATIONAL AIDS VACCINE INITIATIVE INC.

INTERNATIONAL AIDS VACCINE INITIATIVE INC.

Company claim

Is this your business?

Get access!

Company Details

Name: INTERNATIONAL AIDS VACCINE INITIATIVE INC.
Jurisdiction: New York
Legal type: FOREIGN NOT-FOR-PROFIT CORPORATION
Status: Active
Date of registration: 14 Feb 1997 (28 years ago)
Entity Number: 2113655
ZIP code: 10004
County: New York
Place of Formation: Delaware
Address: 125 broad street, 9th floor, NEW YORK, NY, United States, 10004

DOS Process Agent

Name Role Address
THE CORPORATION DOS Process Agent 125 broad street, 9th floor, NEW YORK, NY, United States, 10004

Unique Entity ID

A UEI is a government-provided number, like a tax ID number, that’s used to identify businesses eligible for federal grants, awards and contracts.

Note: In April 2022, the federal government replaced its old identifier of choice, the Data Universal Numbering System (DUNS) number, with a government-issued UEI. Now all the federal government’s Integrated Award Environment systems use UEI numbers instead of DUNS numbers. So any entity doing business with the federal government must register for a UEI.

Unique Entity ID:
ZEJBC8JQM3P5
CAGE Code:
44YM6
UEI Expiration Date:
2025-11-27

Business Information

Doing Business As:
INTERNATIONAL AIDS VACCINE INITIATIVE INC
URL:
http://www.iavi.org/
Activation Date:
2024-12-02
Initial Registration Date:
2005-09-19

Commercial and government entity program

The The Commercial And Government Entity Code (CAGE) is assigned by the Department of Defense's Defense Logistics Agency (DLA) and represents your company's physical address for GSA's mailings, payments, and administrative records.

Note: A CAGE Code enables a company to contract with the U.S. government, allowing bid on government contracts and to receive government payments. Also for business this means that it's a Verified business entity and Has a validated physical address.

CAGE number:
44YM6
Status:
Active
Type:
Non-Manufacturer
CAGE Update Date:
2025-05-13
CAGE Expiration:
2029-12-02
SAM Expiration:
2025-11-27

Contact Information

POC:
AMIRA BASEL
Corporate URL:
http://www.iavi.org/

Form 5500 Series

Employer Identification Number (EIN):
133870223
Plan Year:
2022
Number Of Participants:
0
Sponsors Telephone Number:
2128471111
File:
View File
Plan Year:
2022
Number Of Participants:
0
Sponsors Telephone Number:
2128471111

History

Start date End date Type Value
2008-07-03 2022-12-12 Address ATTN: GENERAL COUNSEL'S OFC, 110 WILLIAM STREET FLOOR 27, NEW YORK, NY, 10038, USA (Type of address: Service of Process)
1997-02-14 2008-07-03 Address VE, INC. C/O ROCKEFELLER CTR., 420 FIFTH AVENUE, NEW YORK, NY, 10018, 2702, USA (Type of address: Service of Process)

Filings

Filing Number Date Filed Type Effective Date
221212002747 2022-12-12 CERTIFICATE OF CHANGE BY ENTITY 2022-12-12
080703000623 2008-07-03 CERTIFICATE OF CHANGE 2008-07-03
970214000676 1997-02-14 APPLICATION OF AUTHORITY 1997-02-14

USAspending Awards / Contracts

Procurement Instrument Identifier:
75N93023F00001
Link:
View Award on USAspending website
Award Or Idv Flag:
AWARD
Award Type:
DELIVERY ORDER
Action Obligation:
70003.00
Base And Exercised Options Value:
70003.00
Base And All Options Value:
70003.00
Awarding Agency Name:
Department of Health and Human Services
Performance Start Date:
2023-09-26
Description:
CONTRACT HHSN272201800010I INTERNATIONAL AIDS VACCINE INITIATIVE; MANUFACTURE OF INFLUENZA VIRUS HUMAN CHALLENGE MATERIAL FOR PHASE I AND II CLINICAL TESTING
Naics Code:
541714: RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)
Product Or Service Code:
AN12: HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH
Procurement Instrument Identifier:
75A50121C00077
Link:
View Award on USAspending website
Award Or Idv Flag:
AWARD
Award Type:
DEFINITIVE CONTRACT
Action Obligation:
1556355.00
Base And Exercised Options Value:
1556355.00
Base And All Options Value:
1556355.00
Awarding Agency Name:
Department of Health and Human Services
Performance Start Date:
2021-09-30
Description:
THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE. THESE VACCINES ARE BASED ON RECOMBINANT EXPRESSION OF FILOVIRUS GLYCOPROTEINS IN
Naics Code:
541714: RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)
Product Or Service Code:
AN42: HEALTH R&D SERVICES; HEALTH CARE - OTHER; APPLIED RESEARCH
Procurement Instrument Identifier:
75N93021F00240
Link:
View Award on USAspending website
Award Or Idv Flag:
AWARD
Award Type:
DELIVERY ORDER
Action Obligation:
-180893.00
Base And Exercised Options Value:
-180893.00
Base And All Options Value:
-180893.00
Awarding Agency Name:
Department of Health and Human Services
Performance Start Date:
2021-07-15
Description:
COORDINATION AND TECHNICAL SUPPORT
Naics Code:
541712: RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT BIOTECHNOLOGY)
Product Or Service Code:
AN11: HEALTH R&D SERVICES; HEALTH CARE SERVICES; BASIC RESEARCH

USAspending Awards / Financial Assistance

Date:
2022-05-25
Link:
View on USAspending
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
DEVELOPMENT OF NOVEL MRNA VACCINES AGAINST MYCOBACTERIUM TUBERCULOSIS - PROJECT SUMMARY/ABSTRACT TUBERCULOSIS REMAINS ONE OF THE TOP TEN LEADING CAUSES OF DEATH WORLDWIDE (1). BASED ON THE MOST CURRENT INFORMATION FROM WHO 2020 REPORT, IN 2019 AN ESTIMATED 1.4 MILLION PEOPLE DIED FROM TB AND APPROXIMATELY 10,000,000 FELL ILL (2). THE COVID-19 PANDEMIC HAS LED TO MASSIVE DECREASES IN TB CASE IDENTIFICATION AND STOP TB ESTIMATES AN ADDITIONAL 1.4 MILLION TB DEATHS WILL BE REGISTERED OVER THE NEXT 4 YEARS (3, 4). THIS, TOGETHER WITH THE GROWING THREAT OF DRUG-RESISTANT TB AND THE CO-EPIDEMICS OF TB WITH HIV AND DIABETES MAKES ENDING THE TB EPIDEMIC MORE CRUCIAL THAN EVER BEFORE. A VACCINE THAT PREVENTS ADOLESCENTS AND ADULTS FROM ACQUIRING, DEVELOPING, AND TRANSMITTING TB WOULD BE THE SINGLE MOST COST-EFFECTIVE TOOL IN ENDING THE TB EPIDEMIC (5). THE TUBERCULOSIS VACCINE INITIATIVE (TBVI) AND TREATMENT ACTION GROUP (TAG) TB VACCINE PIPELINES REPORT TWELVE SUBUNIT VACCINES INCLUDING RECOMBINANT PROTEIN/ADJUVANT AND VIRAL VECTOR VACCINES SPANNING FROM PRECLINICAL THROUGH PHASE 3 DEVELOPMENT (6, 7). OF THESE, NINE INCLUDE AG85 (AG85A OR B) AND SIX INCLUDE ESAT6. THE HIGHLY LIMITED ANTIGENIC AND IMMUNOLOGICAL DIVERSITY PRESENT IN THE PIPELINE IS A SIGNIFICANT GAP IN EFFORTS TO DEVELOP A NOVEL, EFFECTIVE VACCINE. THE PROPOSED RESEARCH IS INTENDED TO BRING NEEDED ANTIGENIC AND PLATFORM DIVERSITY TO THE PRE-CLINICAL TB VACCINE PIPELINE USING MODERNA’S CUTTING-EDGE MRNA VACCINE TECHNOLOGY AND EXPERTISE. WITHIN THE R61 PHASE OF THIS PROGRAM, WE WILL FIRST OPTIMIZE MYCOBACTERIAL ANTIGEN SEQUENCES FOR EXPRESSION IN MAMMALIAN CELLS USING MODERNA’S PROPRIETARY LEARNINGS AND ALGORITHMS. THESE PRINCIPLES WILL BE APPLIED TO THE DEVELOPMENT OF THREE CANDIDATE MRNA VACCINES, INCLUDING 1) AN ANTIGEN CASSETTE PREVIOUSLY SHOWN TO INDUCE PROTECTION IN ANIMAL MODELS WHEN DELIVERED AS A PROTEIN PLUS ADJUVANT, 2) A NEW ANTIGEN CASSETTE INCLUDING NOVEL ANTIGENS, AND 3) THE M72 ANTIGEN SHOWN TO INDUCE PROTECTION IN HUMANS WHEN DELIVERED AS RECOMBINANT PROTEIN WITH THE AS01E ADJUVANT. WE WILL THEN USE DATA FROM MURINE IMMUNOGENICITY AND PROTECTION STUDIES TO SELECT THE TWO BEST CANDIDATES FOR ADVANCEMENT INTO THE R33 PHASE. WITHIN THE R33 PHASE, WE WILL USE THE GUINEA PIG CHALLENGE MODEL TO DOWNSELECT TO A FINAL LEAD CANDIDATE FOR FURTHER ADVANCEMENT. ONCE A FINAL LEAD CANDIDATE IS SELECTED, ADDITIONAL STUDIES WILL BE CONDUCTED TO FURTHER CHARACTERIZE THE CANDIDATE, INCLUDING PROTECTION IN GENETICALLY DIVERSE MICE AND AN IMMUNOGENICITY STUDY IN NONHUMAN PRIMATES TO OPTIMIZE THE VACCINATION REGIMEN FOR CLINICAL USE. BY THE END OF THIS PROGRAM, WE WILL HAVE A NOVEL LEAD VACCINE CANDIDATE READY FOR ADVANCEMENT INTO IND- ENABLING STUDIES AND EARLY DEVELOPMENT AS A VACCINE TO PREVENT TB DISEASE IN ADULTS AND ADOLESCENTS.
Obligated Amount:
1336253.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2021-04-15
Link:
View on USAspending
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
6TH GLOBAL FORUM ON TB VACCINES - PROJECT SUMMARY/ABSTRACT THE GLOBAL FORUM ON TB VACCINES (GLOBAL FORUM) IS THE WORLD’S LARGEST GATHERING OF STAKEHOLDERS STRIVING TO DEVELOP NEW VACCINES TO PREVENT TUBERCULOSIS (TB). IN 2018, TB KILLED AN ESTIMATED 1.5 MILLION PEOPLE, MORE THAN ANY OTHER SINGLE INFECTIOUS DISEASE AGENT, AND 10 MILLION BECOME SICK WITH THE DISEASE (1). THE UNITED NATIONS’ SUSTAINABLE DEVELOPMENT GOALS (SDGS), THE WORLD HEALTH ORGANIZATION’S (WHO) END TB STRATEGY, AND THE STOP TB PARTNERSHIP’S GLOBAL PLAN TO END TB 2018-2022 RECOGNIZE THAT NEW VACCINES WILL BE IMPERATIVE TO REACHING GLOBAL TARGETS TO ELIMINATE TB; AND WORLD LEADERS COMMITTED TO SUPPORTING RESEARCH AND DEVELOPMENT (R&D) OF NEW TOOLS TO END TB IN THE POLITICAL DECLARATION FROM THE UNITED NATIONS HIGH-LEVEL MEETING ON TB IN 2018. THE GLOBAL FORUM PROVIDES A UNIQUE OPPORTUNITY FOR THE TB VACCINE R&D COMMUNITY TO COME TOGETHER TO REVIEW THE STATE OF THE FIELD, SHARE THE LATEST RESEARCH AND FINDINGS, AND IDENTIFY NEW AND INNOVATIVE APPROACHES TO TB VACCINE R&D. PROGRAM TOPICS RANGE FROM BASIC RESEARCH TO CLINICAL TRIALS, LICENSURE, ACCESS, AND ADVOCACY. THE 6TH GLOBAL FORUM ON TB VACCINES IS PLANNED TO TAKE PLACE IN TOULOUSE, FRANCE FROM APRIL 20 – 22, 2021. THE EUROPEAN REGION HAS LONG BEEN AT THE FOREFRONT OF TB VACCINE RESEARCH AND INNOVATION; AND FRANCE’S LEADERSHIP AND COMMITMENT TO GLOBAL HEALTH, ITS EXCELLENCE IN TUBERCULOSIS (TB) VACCINE RESEARCH, AND TOULOUSE’S REPUTATION AS A KNOWLEDGE HUB AND CENTER FOR INNOVATION MAKE THIS AN EXCITING AND APPROPRIATE VENUE FOR THE 6TH GLOBAL FORUM. AS WITH PAST GLOBAL FORUMS, THE 6TH GLOBAL FORUM WILL PROVIDE A PLATFORM FOR SCIENTIFIC EXCHANGE AND GLOBAL DISCOURSE ON THE PATH FORWARD FOR TB VACCINE R&D, AS WELL AS OPPORTUNITIES TO IDENTIFY POTENTIAL PARTNERS AND COLLABORATORS. THE ORGANIZERS WILL SEEK WAYS TO ENHANCE NETWORKING OPPORTUNITIES, PROMOTE INTERACTIONS AMONGST PARTICIPANTS, AND BRING TOGETHER PARTICIPANTS WITH COMMON INTERESTS. ADDITIONALLY, THE GLOBAL FORUM ENCOURAGES AND SUPPORTS EARLY CAREER RESEARCHERS IN SHARING THEIR RESEARCH AND OFFERS MULTIPLE OPPORTUNITIES TO LEARN FROM AND ENGAGE WITH EXPERTS IN THE FIELD. IAVI IS REQUESTING FUNDING FROM THE NIH TO SUPPORT TRAVEL FOR EARLY-CAREER RESEARCHERS AND PARTICIPANTS FROM TB ENDEMIC COUNTRIES WHO WOULD NOT OTHERWISE HAVE THE RESOURCES TO ATTEND, PRESENT THEIR RESEARCH, OR PARTICIPATE IN THE DISCUSSIONS THAT TAKE PLACE AT THE 6TH GLOBAL FORUM. THE 6TH GLOBAL FORUM WILL FOLLOW ON THE 5TH GLOBAL FORUM IN NEW DELHI, INDIA (2018); 4TH GLOBAL FORUM IN SHANGHAI, CHINA (APRIL 2015); 3RD GLOBAL FORUM IN CAPE TOWN, SOUTH AFRICA (MARCH 2013); AND 2ND GLOBAL FORUM IN TALLINN, ESTONIA (SEPTEMBER 2010). THE FIRST GLOBAL FORUM ON TB VACCINES WAS ORGANIZED BY THE WHO AND TOOK PLACE IN GENEVA IN 2001.
Obligated Amount:
6500.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2025-02-26
Link:
View on USAspending
Awarding Agency Name:
Department of Defense
Transaction Description:
ADVANCING A PROMISING TUBERCULOSIS VACCINE CANDIDATE: MTBVAC DE-OBLIGATE FUNDS TO CLOSE AWARD 1. PER SECTION 711 OF THE NATIONAL DEFENSE AUTHORIZATION ACT (NDAA) 2019, THE US ARMY MEDICAL RESEARCH ACQUISITION ACTIVITY (USAMRAA), US ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND (USAMRDC) TRANSFERRED TO THE DEFENSE HEALTH AGENCY (DHA) FROM THE U.S. ARMY EFFECTIVE 01 OCTOBER 2022. THIS MODIFICATION REFLECTS CHANGES CONSISTENT WITH THE TRANSFER TO DHA. 2. DIVISION II HAS BEEN UPDATED TO SUPERSEDE DIVISION III, PART 2, SECTION C, 2.B. ELECTRONIC PAYMENT INSTRUCTIONS
Obligated Amount:
-28092.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2020-04-14
Link:
View on USAspending
Awarding Agency Name:
Small Business Administration
Transaction Description:
TO AID SMALL BUSINESSES IN MAINTAINING WORK FORCE DURING COVID-19 PANDEMIC.
Obligated Amount:
0.00
Face Value Of Loan:
3429355.00
Total Face Value Of Loan:
3429355.00
Date:
2019-04-10
Link:
View on USAspending
Awarding Agency Name:
Department of Defense
Transaction Description:
ADVANCING A PROMISING TUBERCULOSIS VACCINE CANDIDATE: MTBVAC CORRECT THE CAGE CODE
Obligated Amount:
6087939.68
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00

Trademarks Section

Serial Number:
76240839
Status:
REGISTERED AND RENEWED
Mark Type:
TRADEMARK, SERVICE MARK
Application Filing Date:
2001-04-13
Mark Drawing Type:
Illustration: Drawing or design without any word(s)/letter(s)/ number(s)
USPTO Link:
View Trademark Status and Document Retrieval (TSDR)

Goods And Services

For:
Educational services, namely, conducting seminars and workshops in the field of AIDS research and development of an AIDS vaccine; development and dissemination of educational materials concerning AIDS research and related access and support services
First Use:
1996-01-25
International Classes:
041 - Primary Class
Class Status:
Sec. 8 – Class(es) in a Multiple Class registration
For:
Printed instructional, educational and teaching materials, namely pamphlets, brochures, books, newsletters, informational flyers and leaflets, in the field of AIDS vaccine research and related research and support services
First Use:
1996-01-25
International Classes:
016 - Primary Class
Class Status:
Sec. 8 – Class(es) in a Multiple Class registration
For:
Charitable fund raising for AIDS vaccine research, patient aid and public and professional education
First Use:
1996-01-25
International Classes:
036 - Primary Class
Class Status:
Sec. 8 – Class(es) in a Multiple Class registration
For:
Medical research; medical counseling and association services, namely promoting public and professional interest in, and awareness of, AIDS vaccine and AIDS-related research, education and support services
First Use:
1996-01-25
International Classes:
042 - Primary Class
Class Status:
Sec. 8 – Class(es) in a Multiple Class registration
Serial Number:
76240261
Mark:
IAVI
Status:
REGISTERED AND RENEWED
Mark Type:
TRADEMARK, SERVICE MARK
Application Filing Date:
2001-04-13
Mark Drawing Type:
Typeset: Word(s)/letter(s)/number(s)
Mark Literal Elements:
IAVI
USPTO Link:
View Trademark Status and Document Retrieval (TSDR)

Goods And Services

For:
Educational services, namely, conducting seminars and workshops in the field of AIDS research and development of an AIDS vaccine; development and dissemination of educational materials concerning AIDS research and related access and support services
First Use:
1996-01-25
International Classes:
041 - Primary Class
Class Status:
Sec. 8 – Class(es) in a Multiple Class registration
For:
[ Printed instructional, educational and teaching materials, namely, pamphlets, brochures, books, newsletters, informational flyers and leaflets, all in the field of AIDS vaccine research and related research and support services ]
First Use:
1996-01-25
International Classes:
016 - Primary Class
Class Status:
Sec. 8 – Class(es) in a Multiple Class registration
For:
Charitable fund raising for AIDS vaccine research, patient aid and public and professional education
First Use:
1996-01-25
International Classes:
036 - Primary Class
Class Status:
Sec. 8 – Class(es) in a Multiple Class registration
For:
Medical research; medical counseling services; association services, namely, promoting the interests of AIDS researchers; promoting public and professional interest in, and awareness of the need for an AIDS vaccine and AIDS-related research, education and support services
First Use:
1996-01-25
International Classes:
042 - Primary Class
Class Status:
Sec. 8 – Class(es) in a Multiple Class registration
Serial Number:
76240257
Mark:
INTERNATIONAL AIDS VACCINE INITIATIVE
Status:
REGISTERED AND RENEWED
Mark Type:
TRADEMARK, SERVICE MARK
Application Filing Date:
2001-04-13
Mark Drawing Type:
Typeset: Word(s)/letter(s)/number(s)
Mark Literal Elements:
INTERNATIONAL AIDS VACCINE INITIATIVE
USPTO Link:
View Trademark Status and Document Retrieval (TSDR)

Goods And Services

For:
Educational services, namely, conducting seminars and workshops in the field of AIDS research and development of an AIDS vaccine; development and dissemination of educational materials concerning AIDS research and related access and support services
First Use:
1996-01-25
International Classes:
041 - Primary Class
Class Status:
Active
For:
Printed instructional, educational and teaching materials, namely, pamphlets, brochures, books, newsletters, informational flyers and leaflets, all in the field of AIDS vaccine research and related research and support services
First Use:
1996-01-25
International Classes:
016 - Primary Class
Class Status:
Active
For:
Charitable fund raising for AIDS vaccine research, patient aid and public and professional education
First Use:
1996-01-25
International Classes:
036 - Primary Class
Class Status:
Active
For:
Medical research; medical counseling services; association services, namely, promoting the interests of AIDS researchers; promoting public and professional interest in, and awareness of the need for an AIDS vaccine and AIDS-related research, education and support services
First Use:
1996-01-25
International Classes:
042 - Primary Class
Class Status:
Active
Serial Number:
76161741
Mark:
MARCH OF DOLLARS
Status:
ABANDONED-FAILURE TO RESPOND OR LATE RESPONSE
Mark Type:
SERVICE MARK
Application Filing Date:
2000-11-07
Mark Drawing Type:
Illustration: Drawing with word(s)/letter(s)/number(s) in Stylized form
Mark Literal Elements:
MARCH OF DOLLARS
USPTO Link:
View Trademark Status and Document Retrieval (TSDR)

Goods And Services

For:
charitable fund raising for AIDS vaccine research, and public and professional education
International Classes:
036 - Primary Class
Class Status:
Active

Tax Exempt

Employer Identification Number (EIN) :
13-3870223
In Care Of Name:
% PATRICK MOUTON
Classification:
Government Instrumentality, Title-Holding Corporation, Charitable Organization, Agricultural Organization, Board of Trade, Pleasure, Recreational, or Social Club, Fraternal Beneficiary Society, Order or Association, Voluntary Employees' Beneficiary Association (Non-Govt. Emps.), Domestic Fraternal Societies and Associations, Teachers Retirement Fund Assoc., Benevolent Life Insurance Assoc., Burial Association, Credit Union, Mutual Insurance Company or Assoc. Other Than Life or Marine, Corp. Financing Crop Operations, Supplemental Unemployment Compensation Trust or Plan, Employee Funded Pension Trust (Created Before 6/25/59), Post or Organization of War Veterans, Legal Service Organization, Black Lung Trust, Multiemployer Pension Plan, Veterans Assoc. Formed Prior to 1880, Trust Described in Sect. 4049 of ERISA, Title Holding Co. for Pensions, etc., State-Sponsored High Risk Health Insurance Organizations, State-Sponsored Workers' Compensation Reinsurance, ACA 1322 Qualified Nonprofit Health Insurance Issuers, Apostolic and Religious Org. (501(d)), Cooperative Hospital Service Organization (501(e)), Cooperative Service Organization of Operating Educational Organization (501(f)), Child Care Organization (501(k)), Charitable Risk Pool, Qualified State-Sponsored Tuition Program, 4947(a)(1) - Private Foundation (Form 990PF Filer)
Ruling Date:
1996-07
Deductibility:
Type of organization and use of contribution: A public charity. Deductibility Limitation: 50% (60% for cash contributions)

Paycheck Protection Program

Date Approved:
2020-04-14
Loan Status:
Paid in Full
SBA Guaranty Percentage:
100
Initial Approval Amount:
3429355
Current Approval Amount:
3429355
Race:
Unanswered
Ethnicity:
Unknown/NotStated
Gender:
Unanswered
Veteran:
Unanswered
Forgiveness Amount:
3477747.01

Reviews Leave a review

This company hasn't received any reviews.

Related by officers

THE CORPORATION

ARSHIA DESIGNS INC. AAA VACUUM CORP. ATLANTICA TELECOM, INC. MISTY SPORTSWEAR, INC. FAT JAMS ELECTRONICS INC. CROQUEMBOUCHE, INC. LONG BEACH PEDIATRIC GROUP, P.C. LAW OFFICES OF JOSEPH A. GRECO, P.C. TEREZ, INC. 732 CINNAMON BEACH INC.

Related by address

125 broad street, 9th floor, NEW YORK, NY, United States, 10004

AIDS VACCINE ADVOCACY COALITION INC.

Date of last update: 01 Apr 2025

Sources: New York Secretary of State

Privacy policy Policy
About us About us
Contacts Contact us

© 2025 bizyork.com, Part of Big Data Integrated